MILBERG WEISS BERSHAD HYNES Sequenom, Inc.
& LERACH, LLP
One Pennsylvania Plaza
New York, New York 10119-0165
(212) 594-5300
BERNSTEIN LIEBHARD & LIFSHITZ, LLP
10 East 40th Street
New York, New York 10016
(212) 779-1414
Co-Liaison Counsel for Plaintiff on
behalf of Plaintiffs' Executive Committee
listed on signature pages
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
-----------------------------------X
COLLEGEWARE USA, INC., on behalf : 01-CV-10831 (SAS)
of itself and all others :
similarly situated, : 21 MC 92 (SAS)
:
Plaintiff, :
: CLASS ACTION COMPLAINT
-against- : FOR VIOLATIONS OF
: FEDERAL SECURITIES LAW
:
SEQUENOM, INC., UBS WARBURG LLC, :
FLEETBOSTON ROBERTSON STEPHENS, :
INC., SG COWEN SECURITIES :
CORPORATION, BEAR, STEARNS & CO. :
INC., DONALDSON, LUFKIN & JENRETTE :
SECURITIES CORPORATION, CHASE H&Q :
(HAMBRECHT & QUIST LLC), LEHMAN : JURY TRIAL DEMANDED
BROTHERS, INC., MERRILL LYNCH, :
PIERCE, FENNER & SMITH, :
INCORPORATED, MORGAN STANLEY DEAN :
WITTER & CO., INCORPORATED, HUBERT :
KOSTER, STEPHEN L. ZANIBONI, and :
HELMUT
SCHUHSLER,
:
:
Defendants. :
-----------------------------------X
SNIPPETS:
One Pennsylvania Plaza New York,
Co-Liaison Counsel for Plaintiff on behalf of Plaintiffs' Executive Committee listed on
SOUTHERN DISTRICT OF NEW YORK -----------------------------------X
INC., DONALDSON, LUFKIN & JENRETTE: SECURITIES CORPORATION, CHASE H&Q:
reports filed by Sequenom,
Form 10-Q's, proxy statements, Quarterly Reports to
the Prospectus and Registration Statement
12 and 15 of the Securities Act of
and Section 27 of the Exchange Act 15 U.S.C. § 78aa.
during the Class Period (including the trading
of Sequenom stock based upon misleading information).
Fenner & Smith Incorporated and Morgan Stanley Dean Witter,
other wrongs complained of herein, the defendants, directly
Plaintiff purchased shares of Sequenom as
Warburg was the bookrunner and a lead underwriter of the
"IPO" or the "Offering").
through its involvement in the Offering of Sequenom shares
Each of the Individual Defendants was provided
press releases alleged herein to be materially false and/or
of all members is impracticable.
Sequenom and the Offering price to the public
excessive and undisclosed commissions from
transactions in Sequenom securities.
offering, according to the executives.
regarding violations of NASD rules connected with the sale
Due to the undisclosed material facts
including, inter alia, Regulation S-K.
or participation in the making of
|
